Blog
The 2021 German Federal Election: What is the Future Outlook for Healthcare in Germany?
Written by Caspar Kengeter and Manon Ricard
International
Blog
What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL
Executive Summary Trinity’s Take: Due to the rapidly evolving rare disease policy environment in China, manufacturers should prepare to take a flexible approach to their rare disease product market access strategy. This would include considering alternative funding opportunities outside of the...
Blog
What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL
Executive Summary Trinity’s Take: While the NRDL presents increasing reimbursement opportunities for oncology products in China, pricing restrictions will remain as a key challenge. In order to defend pricing in NRDL negotiations, manufacturers should consider targeting indications with high unmet needs...
Blog
Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment
Executive Summary Trinity’s Take: Based on the short-term follow up sales data, the increase in average sales revenue and volume growth offset the average price discount for the majority of NRDL listed products in 2017, which justifies the steep price cut...
Blog
Poland’s Medical Fund Bill to Improve Access to Oncology Drugs
Executive Summary Trinity’s Take: The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified...
Blog
2019 NRDL: Insights for Future Pricing Negotiations in China
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed...
